Dupilumab Reduction of IgE Levels and Probability of Atopic Dermatitis Flares – Analysis of A Randomized Placebo-Controlled 52-Week Study
Brian Kim(Icahn School of Medicine at Mount Sinai), Sonya Cyr(Regeneron (United States)), Eric L. Simpson(Oregon Health & Science University), Lawrence F. Eichenfield(University of California San Diego), Jonathan I. Silverberg(George Washington University), Lisa A. Beck(University of Rochester Medicine), Kilian Eyerich(University Medical Center Freiburg), Zhen Chen(The First People's Hospital of Shunde), Shinichi Imafuku, Ana B. Rossi(Sanofi (United States))
Cited by 6
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k